img

ACC 2022

Here are the most important scientific articles of the ACC 2022 Congress.

If you cannot view the articles, click here

ACC 2022

ACC 2022 | FLAVOUR Study: FFR and IVUS in Intermediate Coronary Lesions
FLAVOUR was a prospective randomized non-inferiority study in patients with intermediate coronary lesions (40%-70%) that compared two imaging modalities: IVUS (intravascular imaging) and FFR ...

ACC 2022

ACC 2022 | COMPLETE
Percutaneous coronary intervention improves angina related quality of life in AMI patients with multivessel disease. The COMPLETE study has shown patients receiving complete revascularization ...

ACC 2022

ACC 2022 | PACMAN AMI
Atherosclerosis plaque causing AMI is often large in volume, high in lipids and have a thin fibrous cap. Statins often reduce atherosclerosis progress, but the impact of PCSK 9 inhibitors ...

ACC 2022

ACC 2022 | IVVE
This randomized study aimed at assessing the flu vaccine vs placebo in patients with cardiac failure.  It included 5129 patients with cardiac failure ...

ACC 2022

ACC 2022 | PROMPT-HF
Patients with cardiac failure with reduced ejection fraction (HFrEF) are sub treated when you look at guideline-directed medical therapy (GDMT).    ...

ACC 2022

ACC 2022 – EDIT-CMD
Roughly 40% of patients receiving a coronary angiography for stable angina (angina episodes twice a week despite medical treatment, lasting 3 months) do not present obstructive coronary artery ...

ACC 2022

ACC 2022 – Complete Trial QoL: Complete Revascularization in STEMI
The COMPLETE study has shown complete revascularization in STEMI reduces cardiovascular mortality or new AMI, which generated a change in ACC/AHA 2021 revascularization guidelines. ...

ACC 2022

ACC 2022 | ADAPT-TAVR: Endoxaban Is Not Superior to DAPT After TAVR
DAPT-TAVR is a randomized trial that tested endoxaban in patients with no indication for anticoagulation who underwent successful transcatheter aortic valve replacement (TAVR) for symptomatic ...

ACC 2022

ACC 2022 | BENTRACIMAB
This study was presented in phase 2, in a healthy population between 50 and 80 years of age, and it showed the use of Bentracimab r everts the antiplatelet effect of ticagrelor.  ...

ACC 2022

ACC 2022 | PACMAN AMI
Atherosclerosis plaque causing AMI is often large in volume, high in lipids and have a thin fibrous cap. Statins often reduce atherosclerosis progress, but the impact of PCSK 9 inhibitors ...

ACC 2022

ACC 2022 – EDIT-CMD
Roughly 40% of patients receiving a coronary angiography for stable angina (angina episodes twice a week despite medical treatment, lasting 3 months) do not present obstructive coronary artery ...

ACC 2022

ACC 2022 | VALOR-HCM: Mavacamten in Adults with Symptomatic Obstructive HCM Eligible for Septal Reduction Therapy
Roughly 50% of hypertrophic cardiomyopathies (HCM) are obstructive, and of this percentage, most of symptoms can be attributed to this condition. Historically, it has been treated with ...

ACC 2022

ACC 2022 – POISE-3: Tranexamic Acid, Bleeding and Cardiovascular Events in Non-Cardiac Surgeries
Tranexamic Acid is an antifibrinolytic which has been shown to reduce bleeding in orthopedic patients and cardiac surgery. But evidence for its use in non-cardiac surgery is still limited.  ...

ACC 2022

ACC 2022 | CLASP TR Study: Tricuspid Valve Repair with the PASCAL Device
The study included 65 patients who received endovascular treatment of the tricuspid valve with the PASCAL device. Forty-six completed the 12-month follow-up. At ...

ACC 2022

ACC 2022 | ADAPT-TAVR: Endoxaban Is Not Superior to DAPT After TAVR
DAPT-TAVR is a randomized trial that tested endoxaban in patients with no indication for anticoagulation who underwent successful transcatheter aortic valve replacement (TAVR) for symptomatic ...

ACC 2022

ACC 2022 | APOLLO
L ipoprotein a (Lp a) is an important risk factor for atherothrombosis and atherosclerotic cardiovascular disease, but it has no approved treatments to this day.   ...

Top